Myelodysplastic syndromes

Introduction: Myelodysplastic syndromes

Myelodysplastic syndromes: A group of syndromes characterized by a disruption in the production of blood cells. Often the bone marrow increases production of various blood cells but because many of them are defective, they are destroyed before the reach the blood stream. More detailed information about the symptoms, causes, and treatments of Myelodysplastic syndromes is available below.

Symptoms of Myelodysplastic syndromes

• Fatigue
• Lightheadedness
• Fever
• Bruising
• Splenomegaly

See full list of 26 symptoms of Myelodysplastic syndromes

Wrongly Diagnosed with Myelodysplastic syndromes?

• Misdiagnosis of Myelodysplastic syndromes
• Underlying causes of Myelodysplastic syndromes (possibly wrongly diagnosed)

Causes of Myelodysplastic syndromes

Read more about causes of Myelodysplastic syndromes.

More information about causes of Myelodysplastic syndromes:

• Myelodysplastic syndromes as a complication caused by other conditions
• Myelodysplastic syndromes as a symptom

Videos for Myelodysplastic syndromes

Patient Surveys for Myelodysplastic syndromes

• Patient Profile Survey
  Take Survey  View Results

Prognosis for Myelodysplastic syndromes

More about prognosis of Myelodysplastic syndromes

Reseach about Myelodysplastic syndromes

Visit our research pages for current research about Myelodysplastic syndromes treatments.

Clinical Trials for Myelodysplastic syndromes

The US based website ClinicalTrials.gov lists information on both federally and privately supported clinical trials using human volunteers.

Some of the clinical trials listed on ClinicalTrials.gov for Myelodysplastic syndromes include:

• Bryostatin 1 in Treating Patients With Myelodysplastic Syndrome - This study has been completed (Current: 23 Nov 2006) - bryostatin 1
• Decitabine in Treating Patients With Myelodysplastic Syndrome - This study is no longer recruiting patients (Current: 23 Nov 2006) - decitabine
• Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer or Other Hematologic or Metabolic Diseases - This study is no longer recruiting patients (Current: 23 Nov 2006) - anti-thymocyte globulin,busulfan,cyclophosphamide,cyclosporine,melphalan,methylprednisolone
• Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome - This study is no longer recruiting patients (Current: 23 Nov 2006) - amifostine,epoetin alfa
• Vaccine Therapy in Treating Patients With Myelodysplastic Syndrome - This study is no longer recruiting patients (Current: 23 Nov 2006) - ras peptide cancer vaccine,sargramostim

See full list of 1210 Clinical Trials for Myelodysplastic syndromes

Statistics for Myelodysplastic syndromes

• Medical statistics for Myelodysplastic syndromes
• Prevalence and incidence statistics for Myelodysplastic syndromes
• Death and Mortality statistics for Myelodysplastic syndromes
• Society statistics for Myelodysplastic syndromes

Stories from Users Related to Myelodysplastic syndromes

• MD vs DO

Related forums and stories:

• Bone Conditions (55)
  • anyone with osteoid osteoma
  • Son has Marfan's Syndrome
  • bone infection
  • after effects of broken femur??
  • extreme pain in elbow
  • More user stories

User Interactive Forums

Read about other experiences, ask a question about Myelodysplastic syndromes, or answer someone else's question, on our message boards:

• I can not get a diagnosis. Please help.
• Tell us your medical story.
• Share your misdiagnosis story.
• What is the best treatment for this?
• See all the forums.

Definitions of Myelodysplastic syndromes:

A myelodysplastic syndrome characterized mainly by dysplasia of the erythroid series. Refractory anemia is uncommon. It is primarily a disease of older adults. The median survival exceeds 5 years. (WHO, 2001) -- 2003 - (Source - Diseases Database)

Myelodysplastic syndromes is listed as a "rare disease" by the Office of Rare Diseases (ORD) of the National Institutes of Health (NIH). This means that Myelodysplastic syndromes, or a subtype of Myelodysplastic syndromes, affects less than 200,000 people in the US population.
Source - National Institutes of Health (NIH)

Ophanet, a consortium of European partners, currently defines a condition rare when it affects 1 person per 2,000. They list Myelodysplastic syndromes as a "rare disease".
Source - Orphanet